Universe Pharmaceuticals (UPC) Accumulated Expenses (2020 - 2025)

Universe Pharmaceuticals (UPC) has 6 years of Accumulated Expenses data on file, last reported at $262.6 million in Q3 2025.

• For the quarter ending Q3 2025, Accumulated Expenses fell 25.57% year-over-year to $262.6 million; the trailing twelve-month figure through Sep 2025 stood at $262.6 million (down 25.57% YoY), and the FY2025 full-year result was $262.6 million, down 25.57% from the prior year.
• Accumulated Expenses retreated to $262.6 million in Q3 2025, from $352.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $352.9 million in Q3 2024 to a low of $444319.0 in Q3 2021.
• A 5-year average of $78.4 million and a median of $2.6 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 100.0% in 2021 and jumped 12912.11% in 2024, its largest moves.
• Tracing UPC's Accumulated Expenses over 5 years: stood at $444319.0 in 2021, then surged by 471.52% to $2.5 million in 2022, then increased by 6.79% to $2.7 million in 2023, then jumped by 12912.11% to $352.9 million in 2024, then slipped by 25.57% to $262.6 million in 2025.
• Business Quant data shows UPC's Accumulated Expenses at $262.6 million in Q3 2025, $352.9 million in Q3 2024, and $2.7 million in Q1 2024.